Pranita D Tamma1, Edina Avdic2, David X Li3, Kathryn Dzintars2, Sara E Cosgrove3. 1. Division of Pediatric Infectious Diseases, Department of Pediatrics, Johns Hopkins University School of Medicine, Baltimore, Maryland. 2. Department of Pharmacy, Johns Hopkins Hospital, Baltimore, Maryland. 3. Division of Infectious Diseases, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland.
Abstract
Importance: Estimates of the incidence of overall antibiotic-associated adverse drug events (ADEs) in hospitalized patients are generally unavailable. Objective: To describe the incidence of antibiotic-associated ADEs for adult inpatients receiving systemic antibiotic therapy. Design, Setting, and Participants: Retrospective cohort of adult inpatients admitted to general medicine wards at an academic medical center. Exposures: At least 24 hours of any parenteral or oral antibiotic therapy. Main Outcomes and Measures: Medical records of 1488 patients were examined for 30 days after antibiotic initiation for the development of the following antibiotic-associated ADEs: gastrointestinal, dermatologic, musculoskeletal, hematologic, hepatobiliary, renal, cardiac, and neurologic; and 90 days for the development of Clostridium difficile infection or incident multidrug-resistant organism infection, based on adjudication by 2 infectious diseases trained clinicians. Results: In 1488 patients, the median age was 59 years (interquartile range, 49-69 years), and 758 (51%) participants were female. A total of 298 (20%) patients experienced at least 1 antibiotic-associated ADE. Furthermore, 56 (20%) non-clinically indicated antibiotic regimens were associated with an ADE, including 7 cases of C difficile infection. Every additional 10 days of antibiotic therapy conferred a 3% increased risk of an ADE. The most common ADEs were gastrointestinal, renal, and hematologic abnormalities, accounting for 78 (42%), 45 (24%), and 28 (15%) 30-day ADEs, respectively. Notable differences were identified between the incidence of ADEs associated with specific antibiotics. Conclusions and Relevance: Although antibiotics may play a critical role when used appropriately, our findings underscore the importance of judicious antibiotic prescribing to reduce the harm that can result from antibiotic-associated ADEs.
Importance: Estimates of the incidence of overall antibiotic-associated adverse drug events (ADEs) in hospitalized patients are generally unavailable. Objective: To describe the incidence of antibiotic-associated ADEs for adult inpatients receiving systemic antibiotic therapy. Design, Setting, and Participants: Retrospective cohort of adult inpatients admitted to general medicine wards at an academic medical center. Exposures: At least 24 hours of any parenteral or oral antibiotic therapy. Main Outcomes and Measures: Medical records of 1488 patients were examined for 30 days after antibiotic initiation for the development of the following antibiotic-associated ADEs: gastrointestinal, dermatologic, musculoskeletal, hematologic, hepatobiliary, renal, cardiac, and neurologic; and 90 days for the development of Clostridium difficileinfection or incident multidrug-resistant organism infection, based on adjudication by 2 infectious diseases trained clinicians. Results: In 1488 patients, the median age was 59 years (interquartile range, 49-69 years), and 758 (51%) participants were female. A total of 298 (20%) patients experienced at least 1 antibiotic-associated ADE. Furthermore, 56 (20%) non-clinically indicated antibiotic regimens were associated with an ADE, including 7 cases of C difficile infection. Every additional 10 days of antibiotic therapy conferred a 3% increased risk of an ADE. The most common ADEs were gastrointestinal, renal, and hematologic abnormalities, accounting for 78 (42%), 45 (24%), and 28 (15%) 30-day ADEs, respectively. Notable differences were identified between the incidence of ADEs associated with specific antibiotics. Conclusions and Relevance: Although antibiotics may play a critical role when used appropriately, our findings underscore the importance of judicious antibiotic prescribing to reduce the harm that can result from antibiotic-associated ADEs.
Authors: Nick W Liu; Kashyap Shatagopam; M Francesca Monn; Hristos Z Kaimakliotis; Clint Cary; Ronald S Boris; Matthew J Mellon; Timothy A Masterson; Richard S Foster; Thomas A Gardner; Richard Bihrle; Michael G House; Michael O Koch Journal: Urol Oncol Date: 2015-08-14 Impact factor: 3.498
Authors: Thamir M Alshammari; E Paul Larrat; Haley J Morrill; Aisling R Caffrey; Brian J Quilliam; Kerry L LaPlante Journal: Am J Health Syst Pharm Date: 2014-01-01 Impact factor: 2.637
Authors: Catherine B Johannes; Najat Ziyadeh; John D Seeger; Ed Tucker; Christoph Reiter; Gerald Faich Journal: Drug Saf Date: 2007 Impact factor: 5.606
Authors: Brian G Bell; Francois Schellevis; Ellen Stobberingh; Herman Goossens; Mike Pringle Journal: BMC Infect Dis Date: 2014-01-09 Impact factor: 3.090
Authors: Marc-Andre Smith; Robert Puckrin; Philip W Lam; Michael J Lamb; Andrew E Simor; Jerome A Leis Journal: JAMA Intern Med Date: 2019-07-01 Impact factor: 21.873
Authors: Thomas L Holland; Issam Raad; Helen W Boucher; Deverick J Anderson; Sara E Cosgrove; P Suzanne Aycock; John W Baddley; Anne-Marie Chaftari; Shein-Chung Chow; Vivian H Chu; Manuela Carugati; Paul Cook; G Ralph Corey; Anna Lisa Crowley; Jennifer Daly; Jiezhun Gu; Ray Hachem; James Horton; Timothy C Jenkins; Donald Levine; Jose M Miro; Juan M Pericas; Paul Riska; Zachary Rubin; Mark E Rupp; John Schrank; Matthew Sims; Dannah Wray; Marcus Zervos; Vance G Fowler Journal: JAMA Date: 2018-09-25 Impact factor: 56.272